In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation

BACKGROUND: Apatinib (YN968D1) is the first small-molecule-targeting drug with anti-tumor activity created in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It showed significant variation in the efficacy for treating cancers, including advanced non-squam...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiani, Zhai, Jingwen, Li, Mingming, Liu, Shiyi, Gong, Xiaobin, Yu, Hongyu, Wei, Hua, Chen, Wansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909954/
https://www.ncbi.nlm.nih.gov/pubmed/36759818
http://dx.doi.org/10.1186/s12935-022-02723-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909954/
https://www.ncbi.nlm.nih.gov/pubmed/36759818
http://dx.doi.org/10.1186/s12935-022-02723-7

Ejemplares similares